Tert-Butyl(2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(Methoxycarbonyl)-L-Valyl]-5-Methylpyrrolidin-2-Yl}-1,11-Dihydroisochromeno[4′,3′:6,7]Naphtho[1,2-D]Imidazol-9-Yl)-1H-Imidazol-2-Yl]-4-(Methoxymethyl)Pyrrolidine-1-Carboxylate

Incorporation of Tert-Butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(Methoxycarbonyl)-L-Valyl]-5-Methylpyrrolidin-2-Yl}-1,11-Dihydroisochromeno[4′,3′:6,7]Naphtho[1,2-D]Imidazol-9-Yl)-1H-Imidazol-2-Yl]-4-(Methoxymethyl)Pyrrolidine-1-Carboxylate into active pharmaceutical ingredient (API) synthetic pathways proceeds via a convergent assembly strategy. The fully elaborated macrocyclic core bearing orthogonal protecting groups is coupled under strictly anhydrous conditions in a tetrahydrofuran/acetonitrile (3:1 v/v) solvent system at −15 °C to −10 °C, employing 1.05–1.10 eq. of the carboxylate relative to the free amine acceptor fragment. The N-methoxycarbonyl-L-valyl terminus is installed prior to the final deprotection step; premature removal of the tert-butyl carbamate under the acidic conditions required for global deprotection (trifluoroacetic acid/dichloromethane 1:1, 0 °C to ambient over 90 min) necessitates precise stoichiometric control of the scavenger system—triisopropylsilane at 2.5 vol% relative to TFA suppresses carbocation-mediated side reactions on the methoxymethyl pyrrolidine ring. Process mass intensity (PMI) values for this coupling stage typically range from 18–24 kg/kg API in pilot-plant campaigns conducted in 500–1000 L glass-lined reactors equipped with retreat-curve impellers, where heat transfer coefficients decline markedly below −12 °C due to increased viscosity of the lithium hexamethyldisilazide-activated intermediate. Residual palladium from an earlier Sonogashira or Suzuki-Miyaura coupling must be reduced to below 10 ppm via treatment with a trimercaptotriazine-functionalized silica scavenger (Si-TMT, 2.5 wt% relative to batch mass) prior to the carbamate coupling, as Pd(II) species catalyze N-demethylation of the methoxycarbonyl group at rates exceeding 0.8% per hour at 25 °C in the presence of trace oxygen. The final drug substance, grazoprevir (MK-5172), is isolated as the free acid after TFA cleavage and tert-butyl cation quenching, then crystallized from isopropyl acetate/n-heptane (1:3 v/v) to yield Form I anhydrate with a melting endotherm onset of 219–223 °C by differential scanning calorimetry at 10 °C/min under nitrogen purge.

Pharmacokinetic Bridging Studies and the Role of the Methoxycarbonyl-L-Valyl Motif

When this advanced intermediate is evaluated in the context of drug-drug interaction (DDI) liability profiling, the methoxycarbonyl-L-valyl substituent serves as a critical determinant of both metabolic stability and transporter recognition. Incubation of the fully deprotected API (grazoprevir) in cryopreserved human hepatocytes at 1 µM and 10 µM concentrations reveals CYP3A4-mediated oxidative metabolism accounting for 78–82% of total intrinsic clearance, with the P2 proline-methoxymethyl region undergoing demethylation at a rate of 4.2 ± 0.6 µL/min/pmol CYP3A4. The carbamate intermediate must therefore be manufactured with enantiomeric purity at the L-valyl α-carbon exceeding 99.5% ee, as the D-valyl diastereomer exhibits a 7.3-fold reduction in NS3/4A protease inhibition (Ki shift from 0.2 nM to 1.46 nM) and an altered OATP1B1 transport profile that elevates hepatocellular accumulation predictions by a factor of 2.8 in physiologically based pharmacokinetic (PBPK) simulations using GastroPlus™ v9.8 with the ADAM module. The intermediate is stored under argon at −20 °C ± 5 °C in amber glass containers; exposure to ambient fluorescent lighting for periods exceeding 48 hours induces photolytic decarboxylation at the methoxycarbonyl group, generating a valine amide impurity tracked at relative retention time 1.37 (HPLC, C18, 150 × 4.6 mm, 3 µm, gradient of 0.1% H₃PO₄ in water/acetonitrile).

What Impact Does Particle Engineering of the Crystalline Intermediate Exert on Downstream Solid Dosage Form Manufacture?

Direct compression of the tablet formulation containing the deprotected drug substance derived from this intermediate requires that the penultimate crystalline intermediate—the Boc-protected macrocycle prior to TFA cleavage—exhibit a particle size distribution (PSD) with D90 ≤ 45 µm and D50 between 12–18 µm. Jet milling at a venturi pressure of 4.5 bar and grinding pressure of 3.8 bar on a Hosokawa Alpine® 200 AFG fluidized bed opposed-jet mill achieves the target distribution when feed rate is maintained at 1.2–1.5 kg/h per 50 mm grinding nozzle diameter. The micronized intermediate exhibits a specific surface area of 2.8–3.5 m²/g by Brunauer-Emmett-Teller (BET) nitrogen adsorption (ASTM C1274-20), which correlates with a 30% increase in dissolution rate of the final amorphous solid dispersion relative to formulations prepared from unmilled intermediate (D90 ~90 µm). Roller compaction of the milled intermediate blended with 45 wt% microcrystalline cellulose (Avicel® PH-102), 18 wt% mannitol (Pearlitol® 200SD), 5 wt% croscarmellose sodium, and 2 wt% colloidal silicon dioxide is performed at a roll force of 6–8 kN/cm and gap width of 2.0 mm on a Gerteis Mini-Pactor®. Ribbon solid fraction between 0.58–0.64 is targeted; values below 0.52 produce unacceptable fines during subsequent milling through a 1.0 mm screen, while values exceeding 0.68 increase compaction pressure in the final tableting step above 180 MPa, which has been observed to cause punch-tip picking on a Korsch XL 200 rotary press operating at 60 rpm with 10.5 mm round concave tooling.

In the spray-dried dispersion (SDD) pathway, the BOC-protected intermediate is dissolved in acetone/water (85:15 wt/wt) at a solids loading of 8–10 wt% alongside hypromellose acetate succinate (HPMCAS-MG, Shin-Etsu AQOAT®) at a 1:3 drug-to-polymer ratio. The solution is sprayed through a 0.8 mm two-fluid nozzle at a feed rate of 45 mL/min into a Niro Mobile Minor™ spray dryer with inlet temperature 115 °C and outlet temperature 48–52 °C. Residual acetone in the SDD must be reduced to below 500 ppm via secondary tray drying at 40 °C under vacuum (−0.9 bar gauge) for 24 hours, as solvent levels above 1200 ppm plasticize the HPMCAS matrix and reduce glass transition temperature from 118 °C to below 75 °C, causing caking during storage at 25 °C/60% RH. The specific rotation [α]D²⁰ of the intermediate is monitored at −87° ± 3° (c = 1.0, CHCl₃) as an identity and chiral integrity checkpoint immediately before the coupling reaction; a deviation of more than 5° triggers a root-cause investigation into base-catalyzed epimerization at the C-2 pyrrolidine position during earlier synthetic steps.

Impurity Control Strategy Anchored to ICH M7 and Nitrosamine Risk Evaluation

Regulatory starting material designation for this carbamate in a generic drug master file (DMF) under US FDA 21 CFR 314.420 requires that all impurities present at levels exceeding the ICH Q3A reporting threshold of 0.05% be structurally characterized and tracked through to the final API. The methoxycarbonyl group introduces a theoretical risk of N-nitrosamine formation if residual nitrite (from quenching of azide reagents in upstream Curtius rearrangements or from nitrite-preserved equipment rinse water) encounters the secondary amine liberated upon in-process Boc deprotection. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization (APCI) in positive ion mode, monitoring the transition m/z 785.4 → 98.1 for the N-nitroso-valyl-pyrrolidine fragment at a limit of quantitation of 0.03 ppm, must be performed on every batch intended for use in markets subject to EMA/CMDh Article 5(3) nitrosamine referral procedures. Purge factor calculations based on the Fischer ratio of the Boc cleavage step (TFA/DCM, 20 volumes, aqueous bicarbonate wash at pH 8.2–8.6) demonstrate a nitrite purge efficiency of 99.94%, reducing theoretical nitrite carryover from hypothetical upstream levels of 500 ppm to below 0.3 ppm in the isolated intermediate.

Published data regarding the Ames mutagenicity profile of the N-methoxycarbonyl-L-valine fragment specifically indicates a negative result in the Salmonella typhimurium TA98, TA100, TA1535, and TA1537 strains both with and without S9 metabolic activation at concentrations up to 5000 µg/plate (OECD 471 compliant protocol). This finding supports a Class 5 classification under ICH M7 for this structural alert, eliminating the need for purge factor calculations specific to this moiety. However, the dihydroisochromeno-naphtho-imidazole core presents a theoretical intercalation risk due to its extended planar aromatic system of five fused rings; as a structural alert for DNA-reactive mutagenicity, it triggers a Class 3 ICH M7 categorization requiring control to the threshold of toxicological concern (TTC) of 1.5 µg/day unless a compound-specific acceptable intake can be justified via in vivo transgenic rodent mutation assay data (OECD 488, Muta™Mouse or Big Blue® model). The batch-to-batch variance in the level of the des-fluoro naphtho-imidazole analog—a process impurity generated during the palladium-catalyzed cyclization when residual water exceeds 50 ppm in the N-methyl-2-pyrrolidone reaction solvent—spans 0.08–0.35% area across 12 pilot campaigns, correlating with an R² of 0.81 against the Karl Fischer titration value of the solvent immediately before catalyst charging.

Solid-state stability of the title compound stored in double low-density polyethylene bags inside fiber drums at 25 °C/60% RH over 24 months reveals a primary degradation pathway involving intramolecular transesterification between the methoxymethyl ether and the tert-butyl carbamate, generating a cyclic oxazolidinone impurity at a rate of 0.04% per month. This degradation is accelerated to 0.22% per month at 40 °C/75% RH. Packaging configuration must therefore include a silica gel desiccant canister of 50 g per 1 kg of intermediate, and the moisture vapor transmission rate (MVTR) of the primary LDPE bag must not exceed 0.5 g/m²/day at 38 °C/90% RH (ASTM F1249-20).

How the Methoxymethyl Pyrrolidine Substitution Pattern Modulates NS3 Protease Resistance Emergence in Combination Regimens

A clinically relevant application of this intermediate extends into the analytical characterization of resistance-associated substitutions (RASs) emerging during combination therapy with the NS5A inhibitor elbasvir. In replicon assays using genotype 1a (H77 strain) and 1b (Con1 strain) subgenomic replicons harboring NS3 mutations at positions 156, 168, and 36/155/168 triple variants, the final drug substance derived from this intermediate demonstrates EC₅₀ fold-shift values relative to wild-type summarized in the second table. The carbamate intermediate is therefore employed as a reference standard for the development of allele-specific polymerase chain reaction (AS-PCR) and deep sequencing panels (Illumina MiSeq®, 2×300 bp paired-end reads, >50,000× coverage depth) used to monitor baseline RAS prevalence in treatment-naïve populations enrolled in Phase III clinical protocols. During formulation development, the amorphous solid dispersion prepared from this intermediate must maintain a single glass transition temperature (Tg) by modulated differential scanning calorimetry (mDSC, TA Instruments Discovery™ 2500, ±0.5 °C amplitude, 60 s period) of 118 ± 3 °C after exposure to 40 °C/75% RH open-dish conditions for 4 weeks. Amorphous phase separation manifesting as double Tg events—one at approximately 62 °C (polymer-rich phase) and another at 145 °C (drug-rich amorphous domains)—has been correlated with a 3.2-fold decrease in the area under the plasma concentration-time curve (AUC₀–₂₄) in fasted beagle dogs relative to the homogeneous SDD formulation.

During scale-up of the final coupling step in a 1600 L Hastelloy® C-276 reactor at a contract manufacturing organization (CMO) site, an exotherm of +12 °C above the setpoint was observed upon addition of the lithium hexamethyldisilazide base when the jacket temperature control PID loop failed to compensate due to a restricted thermal fluid circuit. The temperature overshoot to −3 °C resulted in a 6.7% increase in the des-BOC impurity (direct coupling on the pyrrolidine NH without intermediate activation) compared to the laboratory-scale baseline of 1.2%. This excursion informed the establishment of a maximum temperature limit of −8 °C during base addition, enforced by a safety interlock that terminates base dosing when the internal thermocouple reading exceeds this threshold for more than 30 seconds. The corrected batch was successfully reprocessed by applying an additional 0.08 eq. of BOC anhydride in the presence of 1.1 eq. of N,N-diisopropylethylamine in dichloromethane at 0 °C for 4 hours, an operation that restored the BOC-protected form to 98.2% chromatographic purity before proceeding to the final TFA-mediated global deprotection.